Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
By Adam L. Cataldo
Merck said its blockbuster cancer drug Keytruda has been approved for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
The Food and Drug Administration approved the use of Keytruda, in combination with carboplatin and paclitaxel, to treat cancer patients based on data from a Phase 3 trial, Merck said Monday.
Keytruda in combination with the other drugs reduced the risk of disease progression or death by 40% in patients whose cancer was mismatch repair proficient, and by 70% in patients whose cancer was mismatch repair deficient, compared with a placebo.
The FDA's approval is the third endometrial carcinoma indication and the 40th indication overall for Keytruda in the U.S., Merck said.
Write to Adam Cataldo at adam.cataldo@wsj.com.
(END) Dow Jones Newswires
June 17, 2024 17:56 ET (21:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks